science
FDA to Reconsider Gene Therapy for Rare Childhood Brain Disorder
The U.S. Food and Drug Administration will review an experimental gene therapy rejected four months earlier. The United States also opened a trade investigation into German plans to cut pharmaceutical spending by $23 billion.
prnewswire.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The U.S. Food and Drug Administration will reconsider approving an experimental gene therapy for a deadly and rare childhood brain disorder that it rejected four months earlier, @statnews reported on June 22, 2026. The agency cleared UniQure last week to submit an application for a Huntington’s disease gene therapy that it had previously rejected.
In a separate action, the United States launched a trade investigation into a German plan to lower spending on pharmaceutical products. The U.S. Trade Representative is conducting the probe under Section 301 of the Trade Act of 1974.
The German Ministry of Health unveiled the overhaul plans in April 2026 to reduce a funding gap by $23 billion through variable discounts on pharmaceuticals. The plan is being replaced after the pharmaceutical industry expressed opposition.
Transparency
1 source · single source
CorroborationModerate · 1 source
